



No. F. 4-17/2025-DD-PS-I(Adv.B-M-3)

Government of Pakistan

Drug Regulatory Authority of Pakistan

Prime Minister's National Health Complex, Park Road Islamabad

Islamabad, the September 23rd, 2025

✓ **M/s. Abbott Laboratories (Pakistan) Ltd.,**
Plot 13, Sector 20, Korangi Industrial Area
Karachi.

Subject: Application for Approval to Advertise Brufen DS Suspension (Reg. No 070851) Through Display Media-Dangler

I am directed to refer to your application regarding the subject cited above and to state that the Advertisement Board in its 3rd meeting held on 4th July, 2025 has approved the advertisement of your product namely Brufen DS Suspension (Reg. No. 070851) through following Media/Mode.

Sr #	Name of Product & Reg. No.	Media of Advertisement
1.	Brufen DS Suspension Reg. No 070851	Display Media i. Dangler

2. The approval of advertisement(s) on Prescribed Form-II is enclosed.

Encl: As Above


(Dr Mahvash Ansari)
Deputy Director

Secretary Advertisement Board,
Drug Regulatory Authority of Pakistan

Copy to the:

- Director (Pharmacy Services) / Chairman, AB, DRAP, Islamabad (e-office)
- The Secretary, Primary & Secondary Healthcare Department, Government of Punjab, Lahore.
- The Secretary, Health Department, Government of Sindh, Karachi.
- The Secretary, Health Department, Government of Khyber Pakhtunkhwa, Peshawar.
- The Secretary, Health Department, Government of Balochistan, Quetta.
- The Secretary, Health Department, Government of Gilgit Baltistan, Gilgit
- The Secretary, Health Department, Government of Azad Jammu & Kashmir, Muzaffarabad.
- The District Health Officer (DHO), Islamabad Capital Territory.
- The Director, Division of QA<, DRAP, Islamabad. (e-office)
- The Additional Director/Officer In-charge, DRAP Lahore, Karachi, Islamabad, Peshawar, Quetta. (e-office)
- Meeting file. (e-office)
- Case file(s). (e-office)



Form – II

[See rule 3(5)]

Government of Pakistan
Drug Regulatory Authority of Pakistan

Ref. No: 4-17/2025-DD-PS-I(Adv.B-M-3)

Date of issuance: 23rd September 2025

Approval for Advertisement of Therapeutic Goods
M/s Abbott Laboratories (Pakistan) Ltd /are hereby permitted to advertise Brufen DS Suspension in <u>Display Media</u> mode(s) of <u>Display Media (Danglers)</u> for a period of two years from the date of issuance unless earlier suspended or cancelled.
Permission of Advertisement granted for (Name): Brufen DS Suspension Registration / Enlistment No. 070851
1. This permission shall be subject to the conditions specified in the Therapeutic Goods (Advertisement) Rules, 2025 under the Drug Regulatory Authority of Pakistan Act, 2012.
2. The advertisement shall be made according to the approved advertisement material/story board (attested copies enclosed) without alteration or modification.
3. The Advertisement Board may withdraw the approval granted or modify or alter the conditions subject to which the advertisement has been approved.
4. This approval is valid for a period of two years only, from the date of issuance of this approval.
5. The Reference No of the advertisement and following additional cautionary statements should also be printed in prominent font size and if aired should be clearly communicated/perceived or understood. i. تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ ii. طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ iii. دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔
6. Approved advertisement specimen enclosed


Secretary
Advertisement Board
(Signatures)
(Stamp)




Chairman
Advertisement Board
(Signatures)
(Stamp)



Front

Dangler

Back

BRUFEN[®] DS
(Ibuprofen)



بخار سے 6-8
گھنٹے تک آرام

Ref: 1. As per SmPC.

Abbott

1. تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ 2. طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ 3. دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔ 4. دوا کو لیبل پر دی گئی ہدایات کے مطابق استعمال کریں۔

PAK2348797.2 (2.1)

BRUFEN[®] DS
(Ibuprofen)



بخار سے 6-8
گھنٹے تک آرام

Ref: 1. As per SmPC.

Abbott

1. تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔ 2. طبیعت زیادہ خراب ہو تو ڈاکٹر سے رجوع کریں۔ 3. دوا کے استعمال سے مضر اثرات کی صورت میں اطلاع متعلقہ کمپنی اور ڈریپ (DRAP) کو دیں۔ 4. دوا کو لیبل پر دی گئی ہدایات کے مطابق استعمال کریں۔

PAK2348797.2 (2.1)

